OBREFCO
Live / Applied — Fourth extension granted (statement of use) (as of 24 Jun 2025)
What this means for you
Not registered yet, but its 29 Jun 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97480903
- Mark type
- Stylized text
- Filed
- 29 Jun 2022
- Published for opposition
- 23 May 2023
- Attorney of record
- Xiomara Triana
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use
Owner
- Bristol-Myers Squibb Company, Princeton, NJ, US
- Bristol-Myers Squibb Company, New York, NY, US
Prosecution history
- 12 Jan 2026 — SOU TEAS EXTENSION RECEIVED
- 24 Jun 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 24 Jun 2025 — SOU EXTENSION 4 GRANTED
- 24 Jun 2025 — SOU EXTENSION 4 FILED
- 24 Jun 2025 — SOU TEAS EXTENSION RECEIVED
- 04 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 07 Jan 2025 — SOU EXTENSION 3 GRANTED
- 07 Jan 2025 — SOU EXTENSION 3 FILED
- 07 Jan 2025 — SOU TEAS EXTENSION RECEIVED
- 08 Jul 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 08 Jul 2024 — SOU EXTENSION 2 GRANTED
- 08 Jul 2024 — SOU EXTENSION 2 FILED
- 08 Jul 2024 — SOU TEAS EXTENSION RECEIVED
- 04 Jan 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 02 Jan 2024 — SOU EXTENSION 1 GRANTED